文献速递头颈部肿瘤放疗

局部晚期头颈癌标准与大剂量分次顺铂联合放疗比较:CisFRad(GORTEC 2015-02)随机II期试验结果

Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
PubMed 文献 · Radiother Oncol · 2024-05-19

该多机构随机II期试验纳入124例局部晚期头颈鳞状细胞癌患者,比较标准大剂量顺铂(HD-Cis:100 mg/m² q3w共3周期)与分次大剂量顺铂(FHD-Cis:25 mg/m²/d d1-4 q3w共3周期)联合同期放疗。主要终点累计顺铂剂量未达统计学显著(FHD-Cis组291 mg/m² vs HD-Cis组274 mg/m²,P=0.054),但FHD-Cis组完成第3周期比例更高(81% vs 64%,P=0.04)且3-4级急性不良事件比例更低(10% vs 17%,P=0.002),两组局部区域失败率、PFS和OS相似。

要点

  • FHD-Cis组累计顺铂剂量291 mg/m² vs HD-Cis组274 mg/m²,P=0.054,主要终点未达统计学显著。
  • FHD-Cis组完成第3周期比例81% vs HD-Cis组64%(P=0.04)。
  • FHD-Cis组3-4级急性不良事件比例10% vs HD-Cis组17%(P=0.002)。

核心结论

  • 主要终点未达到,但FHD-Cis较标准治疗允许更多周期顺铂被给予且毒性更低。
  • FHD-Cis联合同期放疗是一种值得进一步考虑的治疗选择。

研究设计与样本

  • 多机构随机II期试验,按术后或根治性同期放化疗分层。
  • 比较HD-Cis(100 mg/m² q3w共3周期)与FHD-Cis(25 mg/m²/d d1-4 q3w共3周期)在局部晚期头颈鳞状细胞癌患者中的效果。
  • 主要终点为累计给予的顺铂剂量。

主要发现

  • 2015年12月至2018年4月共随机124例患者。
  • 中位累计顺铂剂量FHD-Cis组291 mg/m²(IQR:251;298)vs HD-Cis组274 mg/m²(IQR:198;295),P=0.054。
  • 接受第3周期顺铂的患者比例FHD-Cis组81% vs HD-Cis组64%(P=0.04)。
  • 3-4级急性不良事件比例FHD-Cis组10% vs HD-Cis组17%(P=0.002)。
  • 中位随访48个月(IQR:41;55),两组局部区域失败率、PFS和OS相似。

临床怎么用

  • 作者认为FHD-Cis联合同期放疗是一种值得进一步考虑的治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemoradiotherapy with high-dose cisplatin (HD-Cis: 100 mg/m2 q3w for three cycles) is the standard of care (SOC) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Cumulative delivered dose of cisplatin is prognostic of survival, even beyond 200 mg/m2 but high toxicity compromises its delivery. AIM: Cisplatin fractionation may allow, by decreasing the peak serum concentration, to decrease toxicity. To date, no direct comparison was done of HD-Cis versus fractionated high dose cisplatin (FHD-Cis). METHODS: This is a multi-institutional randomized phase II trial, stratified on postoperative or definitive chemoradiotherapy, comparing HD-Cis to FHD-Cis (25 mg/m2/d d1-4 q3w for 3 cycles) in patients with LA-HNSCC. The primary endpoint was the cumulative delivered cisplatin dose. RESULTS: Between December 2015 and April 2018, 124 patients were randomized. Median cisplatin cumulative delivered dose was 291 mg/m2 (IQR: 251;298) in the FHD-Cis arm and 274 mg/m2 (IQR: 198;295) in the HD-Cis arm (P = 0.054). The proportion of patients receiving a third cycle of cisplatin was higher, with a lower proportion of grade 3-4 acute AEs in the FHD-Cis arm compared to the HD-Cis arm: 81 % vs. 64 % (P = 0.04) and 10 % vs. 17 % (P = 0.002), respectively. With a median follow-up of 48 months (IQR: 41;55), locoregional failure rate, PFS and OS were similar between the two arms. CONCLUSION: Although the primary endpoint was not met, FHD-Cis allowed more cycles of cisplatin to be delivered with lower toxicity, when compared to SOC. FHD-Cis concurrently with RT is a treatment option which deserves further consideration.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Borel C, Sun XS, Coutte A, et al. Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiother Oncol. 2024. PMID: 38768714. doi:10.1016/j.radonc.2024.110329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。